Fulgent Genetics Balance Sheet Health
Financial Health criteria checks 4/6
Fulgent Genetics has a total shareholder equity of $1.1B and total debt of $1.2M, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are $1.2B and $102.0M respectively.
Key information
0.1%
Debt to equity ratio
US$1.18m
Debt
| Interest coverage ratio | n/a |
| Cash | US$424.15m |
| Equity | US$1.13b |
| Total liabilities | US$102.04m |
| Total assets | US$1.24b |
Recent financial health updates
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Recent updates
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09Fulgent Genetics: Sell Volatility
Jan 26Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy
Jan 09Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot
Dec 20I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease
Dec 14Fulgent: Now Cheap Enough
Dec 06Financial Position Analysis
Short Term Liabilities: FLGT's short term assets ($507.8M) exceed its short term liabilities ($73.0M).
Long Term Liabilities: FLGT's short term assets ($507.8M) exceed its long term liabilities ($29.0M).
Debt to Equity History and Analysis
Debt Level: FLGT has more cash than its total debt.
Reducing Debt: FLGT's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Debt Coverage: FLGT's debt is well covered by operating cash flow (2282.6%).
Interest Coverage: Insufficient data to determine if FLGT's interest payments on its debt are well covered by EBIT.